Israel Biotech Fund ready to expand portfolio after closing $112 million second fund
Israel Biotech Fund (IBF), founded by Dr. David Sidransky, Dr. Yuval Cabilly and Ido Zairi, announced the closing of its second fund with a total of $112 million. The fund will focus on the investment and formation of Israeli biotech and pharma companies developing drugs at different stages of development and for various indications. Amongst the main limited partners of fund II are Harel Insurance, BMS, an international pharmaceutical company, and the CBG fund. The second fund will continue its collaboration with the international advisory team of the fund, which includes, among others, Dr. S...